PATENT CLAIM ANALYSIS

Application Number: 16185271
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "293000"]

Abstract:
Methods for treating a subject having a cancerous tumor are disclosed. The methods comprise administering to the subject an effective amount of a non-steroidal selective glucocorticoid receptor modulator (SGRM) and an effective amount of a chemotherapeutic agent. The tumor may be cervical cancer. The SGRM may be a fused azadecalin. In embodiments, the SGRM may be a heteroaryl ketone fused azadecalin or an octahydro fused azadecalin.

Claim (Index 12):
A method of treating a subject hosting a cervical cancer tumor, the method comprising administering to the subject an effective amount of a chemotherapeutic agent and orally administering an effective amount of non-steroidal selective glucocorticoid receptor modulator (SGRM) to reduce the tumor load of the cervical cancer tumor, wherein the SGRM is an octahydro fused azadecalin has compound having the following formula: wherein R 1  is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R 1a ; each R 1a  is independently selected from the group consisting of hydrogen, C 1-6  alkyl, halogen, C 1-6  haloalkyl, C 1-6  alkoxy, C 1-6  haloalkoxy, N-oxide, and C 3-8  cycloalkyl; ring J is selected from the group consisting of an aryl ring and a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S; each R 2  is independently selected from the group consisting of hydrogen, C 1-6  alkyl, halogen, C 1-6  haloalkyl, C 1-6  alkoxy, C 1-6  haloalkoxy, C 1-6  alkyl-C 1-6  alkoxy, CN, OH, NR 2a R 2b , C(O)R 2a , C(O)OR 2a , C(O)NR 2a R 2b , SR 2a , S(O)R 2a , S(O) 2 R 2a , C 3-8  cycloalkyl, and C 3-8  heterocycloalkyl having from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S; alternatively, two R 2  groups on adjacent ring atoms are combined to form a heterocycloalkyl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, wherein the heterocycloalkyl ring is optionally substituted with from 1 to 3 R 2c  groups; R 2a , R 2b  and R 2c  are each independently selected from the group consisting of hydrogen and C 1-6  alkyl; each R 3a  is independently halogen; and subscript n is an integer from 0 to 3, or salts and isomers thereof.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 98.0
- Lexical Diversity: 1.64444
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15942312', '15915477', '16150916', '15697878', '15987365']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7975335697371254
- 35 USC 102 Novelty (BERT): 0.6181314959057189
- Combined Prediction Score: 0.7795933623539848
- Mean Citation Score: 499.5320019999999
- Max Citation Score: 564.31116
- Similarity Product: 507.38269506342886

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test